Table 1 Overview of questionnaire, and treatment data for the cross-sectional sample
Non-NPSLE | NPSLE | |
|---|---|---|
No. of subjects | 29 | 33 |
Age range (median) | 23–56 (38) | 22–55 (44) |
Disease duration (years) | 17.0 (4.1–26.9) | 14.0 (4.0–28.0) |
SDI-score | 0.0 (0.0–1.6) | 1.0 (0.0–4.0) |
SLEDAI2k-score | 2.0 (0.0–5.2) | 0.0 (0.0–9.1) |
anti-nuclear antibodies | 29 (100%) | 31 (93%) |
anti-ds-DNA antibodies | 18 (62%) | 21 (63%) |
anti Sm-nuclear antigen | 5 (17%) | 3 (9%) |
Glucocorticoids | 18 (62%) | 21 (63%) |
Daily dose of glucocorticoids | 2.0 (0.0–10.0) | 4.5 (0.0–10.0) |
Antimalarials | 26 (89%) | 25 (75%) |
Cyclophosphamide | 0 (0%) | 0 (0%) |
Azathioprine | 2 (6%) | 13 (39%) |
Cyclosporine A | 2 (6%) | 0 (0%) |
MMF | 4 (13%) | 6 (18%) |
Rituximab | 1 (3%) | 1 (3%) |
IVIG | 1 (3%) | 1 (3%) |
Methotrexate | 1 (3%) | 3 (9%) |
Belimumab | 8 (27%) | 3 (9%) |
Antihypertensive treatment | 5 (17%) | 9 (27%) |
aPL+ | 5 (17%) | 14 (42%) |